FMR CORP 13D and 13G filings for Xenon Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-07 10:01 am Purchase |
2025-02-28 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 7,851,098 10.300% |
983,414 (+14.32%) |
Filing |
| 2024-11-12 10:40 am Purchase |
2024-11-08 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 6,867,684 9.064% |
1,211,762 (+21.42%) |
Filing |
| 2024-02-09 10:05 am Purchase |
2024-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 5,655,922 7.556% |
965,093 (+20.57%) |
Filing |
| 2023-02-09 12:46 pm Purchase |
2023-02-09 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 4,690,829 7.500% |
780,812 (+19.97%) |
Filing |
| 2022-02-09 10:04 am Purchase |
2022-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 3,910,017 7.579% |
1,284,465 (+48.92%) |
Filing |
| 2021-02-08 10:35 am Purchase |
2021-02-05 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 2,625,552 7.499% |
2,625,552 (New Position) |
Filing |